MedTrace Logo

Open-label Trial of Leukine in Active Crohn's Disease

NCT00206700 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2013-12-04

No results posted yet for this study

Summary

The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.

Conditions

  • Crohn Disease

Interventions

DRUG

Sargramostim (Leukine)

Open Label, 8 week cycle

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • New Zealand
  • Russia
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206700 on ClinicalTrials.gov